• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, November 21, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT

by
November 17, 2026
in Cancer, Health
Reading Time: 3 mins read
0
Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT

Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A retrospective investigation has demonstrated that machine learning classifiers trained on organ-specific dosiomic features can accurately predict late genitourinary adverse events in patients undergoing stereotactic body radiation therapy for localized prostate cancer. Published in BMC Cancer, the study evaluated treatment plans generated for CyberKnife robotic radiosurgery to determine whether advanced spatial radiation metrics could identify patients at risk of chronic urinary toxicity more effectively than conventional planning tools and clinical assessments.

The study evaluated a cohort of eighty-seven patients diagnosed with localized prostate adenocarcinoma who underwent extreme hypofractionation delivered via the CyberKnife system. Treatment regimens delivered total radiation doses ranging from 35 to 36.25 Gray administered across five treatment fractions. Following therapy, patients were monitored over an extended observation timeline spanning up to five years to document post-treatment complications.

The clinical endpoint examined by the investigators was the development of late genitourinary adverse events classified as grade 1 or higher according to the Radiation Therapy Oncology Group grading criteria. To ensure the analysis strictly addressed delayed complications rather than acute reactions, the primary endpoint was restricted to toxicities emerging beyond six months post-radiation. Within the analyzed patient group, late genitourinary adverse events were documented in 17.2 percent of individuals.

To capture fine-grained radiation distribution data, researchers employed the PyRadiomics package to extract high-dimensional dosiomic features from multiple anatomical contours. These regions of interest included the prostate gland, the planning target volume, the urinary bladder, the rectum, the penile bulb, and a surrogate urethra model. The investigators established four distinct predictive models built on identical patient datasets and partitions: one relying on clinical and patient-reported variables, one utilizing traditional dose-volume histogram metrics, one utilizing extracted dosiomics, and a fourth combining all parameter blocks.

Model training incorporated an eighty-twenty patient-level train-test partition combined with feature filtering and least absolute shrinkage and selection operator regression. Classifiers were trained applying group-aware cross-validation and class weighting to address class imbalance. Final model validation on the independent hold-out test set demonstrated that the dosiomic model achieved the strongest discriminative capability, recording a receiver operating characteristic area under the curve of 0.92 and a precision-recall area under the curve of 0.84 against a baseline prevalence reference of 0.167. In comparison, the combined model achieved an area under the curve of 0.90, the dose-volume histogram model achieved 0.86, and the clinical model achieved 0.46. Balanced accuracy reached 0.80 for dosiomics, outperforming the dose-volume metric score of 0.70 and the clinical model score of 0.43.

Further analysis revealed that integrating conventional dose-volume statistics and clinical variables into the dosiomic framework failed to improve discriminative accuracy over dosiomic parameters alone. To ensure clinical transparency, the investigators performed SHapley Additive exPlanations analysis, which isolated a compact set of interpretable risk predictors. These influential features captured both organ geometry and spatial dose heterogeneity across the bladder, urethra, and prostate. While these findings highlight the predictive value of dosiomic analysis in radiosurgery planning, the authors noted that multicenter validation remains necessary to establish model generalizability.

The evaluation incorporated bootstrap confidence intervals across the independent testing phase. For precision-recall metrics, the dosiomic model achieved a 95 percent confidence interval of 0.53 to 1.00, while the combined framework yielded an interval of 0.37 to 1.00. The dose-volume histogram model generated a confidence interval spanning 0.35 to 1.00, and the clinical model recorded a range between 0.16 and 0.37.

Regarding discrimination across receiver operating curves, the dosiomic approach demonstrated a 95 percent confidence interval spanning 0.69 to 1.00. Corresponding confidence intervals reached 0.73 to 1.00 for the combined strategy, 0.68 to 1.00 for dose-volume histograms, and 0.22 to 0.70 for clinical variables. The methodology also assessed feature selection stability across independent training sets and related SHAP contributions directly to conventional dose-volume metrics.

Subject of Research: Dosiomics-based machine learning prediction of late genitourinary toxicity following CyberKnife prostate SBRT

Article Title: Dosiomics-based prediction of late genitourinary side-effects after CyberKnife for prostate cancer: a SHAP-explainable machine learning approach

Article References: Mottareale, R., Serra, M., Pezzulla, D., Cilla, S., Borzillo, V., Scipilliti, E., Franzese, D., Perdonà, S., Passaro, F., Izzo, A., Rossetti, S., Pignata, S., Ametrano, G., d’Alesio, V., Buonanno, F., Arrichiello, C., Mercogliano, S., Di Franco, R., & Ravo, V. (2026). Dosiomics-based prediction of late genitourinary side-effects after CyberKnife for prostate cancer: a SHAP-explainable machine learning approach. BMC Cancer. https://doi.org/10.1186/s12885-026-17279-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17279-2

Keywords: prostate cancer, CyberKnife, stereotactic body radiation therapy, dosiomics, machine learning, genitourinary toxicity, SHAP analysis, PyRadiomics, radiation oncology, dose-volume histogram, RTOG scale, prostate adenocarcinoma, treatment planning, predictive modeling, surrogate urethra model, spatial heterogeneity

News Source: Nathaniel Bowman. (November 17, 2026). Dosiomics Machine Learning Model Predicts Late Urinary Toxicity After Prostate CyberKnife SBRT. Scienmag.

Tags: CyberKnifedose-volume histogramdosiomicsgenitourinary toxicityMachine Learningpredictive modelingprostate adenocarcinomaProstate CancerPyRadiomicsradiation oncologyRTOG scaleSHAP analysisSpatial heterogeneitystereotactic body radiation therapysurrogate urethra modeltreatment planning
Share12Tweet7Share2ShareShareShare1

Related Posts

Plasma Proteomics Reveals Distinct Resistance and Survival Signatures in Lung Cancer

Plasma Proteomics Reveals Distinct Resistance and Survival Signatures in Lung Cancer

November 21, 2026
Alternative CAR Cell Therapies Show Promise Against Aggressive Pleural Mesothelioma

Alternative CAR Cell Therapies Show Promise Against Aggressive Pleural Mesothelioma

November 21, 2026

Ginsenoside Rh3 Alleviates Cisplatin-Induced Kidney Damage in Mouse and Cell Models

November 21, 2026

Betaine Eases Liver Steatosis in Mice by Modulating RNA Translation Efficiency

November 21, 2026

POPULAR NEWS

  • Enhanced 3D ResNet Model Classifies Active Pulmonary Tuberculosis on Chest CT

    Enhanced 3D ResNet Model Classifies Active Pulmonary Tuberculosis on Chest CT

    29 shares
    Share 12 Tweet 7
  • Analysis of Real-World Data Details Skin Toxicities Across Eleven Targeted Cancer Drugs

    29 shares
    Share 12 Tweet 7
  • Lightweight CPU Fingerprinting Enhances Post-Quantum BIKE Key Generation Against Seed Prediction

    29 shares
    Share 12 Tweet 7
  • Regional Biopsy Matches Standard Sampling for Suspected Prostate Cancer Across PI-RADS Scores

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Plasma Proteomics Reveals Distinct Resistance and Survival Signatures in Lung Cancer

Alternative CAR Cell Therapies Show Promise Against Aggressive Pleural Mesothelioma

Ginsenoside Rh3 Alleviates Cisplatin-Induced Kidney Damage in Mouse and Cell Models

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.